This includes an emphasis on therapies commonly used for the treatment of high-grade serous ovarian cancers (e.g., platinum, taxanes, PARP inhibitors, and anti-angiogenic agents). The gene discussed is PARP1; the disease is ovarian serous adenocarcinoma.